Remyelination promotion by mesenchymal stem cells

"Remyelination promotion by mesenchymal stem cells" does **not** refer to a single molecule, receptor, enzyme, transporter, or other canonical drug target. Instead, it describes a **therapeutic strategy** using **mesenchymal stem cells (MSCs)**—multipotent stromal/stem cells capable of self-renewal and differentiation—to promote the repair/regeneration of myelin sheaths in diseases such as multiple sclerosis. The beneficial effects arise from several mechanisms: - Immunomodulatory actions that suppress harmful inflammation within the central nervous system. - Secretion of neurotrophic factors via paracrine signaling that supports survival and function of neurons and glial progenitors. - Stimulation/recruitment/differentiation support for endogenous oligodendrocyte precursor cells responsible for new myelin formation. MSCs themselves are being investigated as cellular therapies rather than being targeted by drugs. Their use is associated with both promise—due to their regenerative potential—and risks such as infection or possible tumorigenicity if improperly managed. This entry should be considered incorrect as a "target" under standard pharmacological definitions because it refers neither to an individual molecule nor receptor but rather an entire class-based cellular intervention strategy.

Other names

Mesenchymal stem cell-mediated remyelinationMSC-induced remyelinationMSC therapy for remyelination

Secretion of anti-inflammatory cytokines and growth factors that promote endogenous repair mechanisms in the central nervous system. Modulation of immune responses to reduce inflammation and support tissue healing in demyelinating diseases like multiple sclerosis. Stimulation of endogenous neural stem cells and oligodendrocyte precursor cells to enhance myelin regeneration.